Intra-Cellular Therapies, Inc.
ITCI
Rank in Stocks
#1684
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Share Price
$131.87
Last synced: 2025-04-02
Market Cap
$12.68B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Intra-Cellular Therapies, Inc. (ITCI)
Category
Healthcare
P/E ratio for Intra-Cellular Therapies, Inc. (ITCI)
P/E ratio as of October 2026 TTM: -183.15
According to Intra-Cellular Therapies, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -183.15. At the end of 2023 the company had a P/E ratio of -49.16.
P/E ratio history for Intra-Cellular Therapies, Inc. from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -183.15 | 58.78% |
| 2024 | -115.35 | 134.61% |
| 2023 | -49.16 | 153.14% |
| 2022 | -19.42 | 29.76% |
| 2021 | -14.97 | 51.85% |
| 2020 | -9.86 | -23.10% |
| 2019 | -12.82 | 219.10% |
| 2018 | -4.02 | -41.27% |
| 2017 | -6.84 | 22.04% |
| 2016 | -5.60 | -69.68% |
| 2015 | -18.48 | 12.19% |
| 2014 | -16.48 | 71.35% |
| 2013 | -9.62 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -119.09% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.